Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Efpeglenatide

INVESTIGATIONAL

Exendin-based GLP-1 receptor agonist

2
graded results
0
ongoing records
2
effect domains
Evidence spread
High evidence 0Moderate evidence 2Low evidence 0Very low evidence 0

Efpeglenatide is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL South Korea; Obesity; Subcutaneous injection; as of 2026-07-13. Hanmi Pharmaceutical

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Efpeglenatide INVESTIGATIONAL
Heart and circulation Decrease
Moderate evidence

In T2D with CVD or kidney disease plus another risk factor, efpeglenatide reduced MACE versus placebo, with a dose-dependent trend, and reduced a kidney composite. An...

Gerstein HC et al., N Engl J Med, 2021 Source
Full findingIn T2D with CVD or kidney disease plus another risk factor, efpeglenatide reduced MACE versus placebo, with a dose-dependent trend, and reduced a kidney composite. An exendin-4-based agent showing hard CV benefit.
PopulationAMPLITUDE-O: N=4076; T2D with CVD or kidney disease; double-blind placebo-controlled RCT; median 1.8 years.
Fundingindustry - Sanofi (efpeglenatide, AMPLITUDE-O; disclosed)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Efpeglenatide INVESTIGATIONAL
renal Decrease
Moderate evidence

AMPLITUDE-O: in T2D with cardiovascular disease or kidney disease plus a risk factor, efpeglenatide reduced a composite renal outcome (decreased kidney function or new...

Gerstein HC et al., N Engl J Med, 2021 Source
Full findingAMPLITUDE-O: in T2D with cardiovascular disease or kidney disease plus a risk factor, efpeglenatide reduced a composite renal outcome (decreased kidney function or new macroalbuminuria) versus placebo (HR 0.68), a prespecified secondary alongside the MACE primary.
PopulationAMPLITUDE-O (NCT03496298): 4076 randomised (2717 efpeglenatide 4/6 mg, 1359 placebo); T2D + CVD or CKD (eGFR 25.0-59.9) + a risk factor; median follow-up 1.81 years; double-blind RCT; SGLT2i-stratified.
Fundingindustry - Sanofi (efpeglenatide, AMPLITUDE-O; disclosed)
Comparatorsplacebo